ConductScience.org, home

Paper34636282

Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy.

Sohail M and 4 others. Expert Rev Anticancer Ther, 2021. Cited by 77 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. Papers, record 34636282. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34636282

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy.
PubMed
Journal
Expert Rev Anticancer Ther
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
5.64
iCite
Revised in PubMed
2022-03-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sohail MMuhammad
2Sun ZZheng
3Li YYanli
4Gu XXuejing
5Xu HHuihttps://orcid.org/0000-0002-0136-4784

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
NeoplasmsMajor topic
Cardiotoxicity
Cell Line, Tumor
Drug Delivery Systems
Female
Humans

Source PubMed

Download CSV of topics

Cited by49

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
42898624Bioengineering strategies to enhance BCG immunotherapy against bladder cancer.Front Immunol2026https://conductscience.org/library/papers/42898624PubMed
42460029Co-formulation of IL-12 mRNA and doxorubicin in polymeric nanoparticles for simultaneous delivery in murine melanoma.RSC Pharm2026https://conductscience.org/library/papers/42460029PubMed
42215521Gold nanoparticles exhibit anticancer property through induction of oxidative stress and autophagy in MCF-7 breast cancer cells.Sci Rep2026https://conductscience.org/library/papers/42215521PubMed
41896273A physics-informed machine learning framework for predicting and mitigating doxorubicin nanocarrier toxicity in normal cells.Sci Rep2026https://conductscience.org/library/papers/41896273PubMed
41739691Linking Metabolomic Diversity to Pharmacological Potency in Anonidium mannii Leaf Extracts.Chem Biodivers2026https://conductscience.org/library/papers/41739691PubMed
41560793Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Mater Today Bio2026https://conductscience.org/library/papers/41560793PubMed
41283276Breast Cancer Progression and Its Theranostic Management via Folate-Directed Targeting of Glycoprotein Receptor.Med Sci (Basel)2025https://conductscience.org/library/papers/41283276PubMed
41195221Effects of histidine and N-acetylcysteine on acute kidney injury induced by doxorubicin in rats: roles of anti-oxidative, anti-inflammatory and anti-apoptotic mechanisms.Vet Res Forum2025https://conductscience.org/library/papers/41195221PubMed
41153808Novel Cross-Cancer Hub Genes in Doxorubicin Resistance Identified by Transcriptional Mapping.Biomedicines2025https://conductscience.org/library/papers/41153808PubMed
41039183Anticancer compounds from Streptomyces: insights from metagenomics and mechanistic perspective.Folia Microbiol (Praha)2025https://conductscience.org/library/papers/41039183PubMed
41022604[Cinnamic acid ameliorates doxorubicin-induced myocardial injury in mice by attenuating cardiomyocyte ferroptosis via inhibiting TLR4].Nan Fang Yi Ke Da Xue Xue Bao2025https://conductscience.org/library/papers/41022604PubMed
41011159A Systematic Review of Advances in Plant-Based Phospholipid Liposomes in Breast Cancer Therapy: Characterization, Innovations, Clinical Applications, and Future Directions.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41011159PubMed
41008599The Emerging Role of Mitochondrial Dysfunction in Thyroid Cancer: Mediating Tumor Progression, Drug Resistance, and Reshaping of the Immune Microenvironment.Biomolecules2025https://conductscience.org/library/papers/41008599PubMed
40789868Dichloroacetate enhances Chemo-sensitivity in wild-type P53 breast cancer cells by modulating ABCG2 and NKG2DL.Sci Rep2025https://conductscience.org/library/papers/40789868PubMed
40764352Abacavir enhances the efficacy of doxorubicin via inhibition of histone demethylase KDM5B in breast cancer.Sci Rep2025https://conductscience.org/library/papers/40764352PubMed
40492153CD20 targeted nanomedicine for GCB-diffuse large B-cell lymphoma through synergistic effects of apoptosis and ferroptosis.Mater Today Bio2025https://conductscience.org/library/papers/40492153PubMed
40281790Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy.Bioengineering (Basel)2025https://conductscience.org/library/papers/40281790PubMed
40277662Temperature- and pH-Responsive Poly(NIPAM-co-HEMA-co-AAm) Nanogel as a Smart Vehicle for Doxorubicin Delivery; Combating Colorectal Cancer.Gels2025https://conductscience.org/library/papers/40277662PubMed
40244536Targeting breast cancer: the promise of phage-based nanomedicines.Breast Cancer Res Treat2025https://conductscience.org/library/papers/40244536PubMed
40231513Exploring SGLT2 Inhibitors' Activity in Breast Cancer: An Overview.Curr Top Med Chem2025https://conductscience.org/library/papers/40231513PubMed

See all 49 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34636282

GET https://conductscience.org/api/papers/v1/34636282/cited_by?page=2